First Hospital In Spain Adopts Xoft Electronic Brachytherapy System For The Treatment Of Early-Stage Breast Cancer, Non-Melanoma Skin Cancer And Gynecological Cancers
-- Technology Continues to Gain Momentum in Europe with Treatment Now Available at Hospital Miguel Servet
-- XOFT System and New Clinical Data on Breast IORT highlighted at European Society for Radiotherapy and Oncology Forum in Barcelona
NASHUA, New Hampshire and BARCELONA, Spain, April 24, 2015 /PRNewswire/ -- (Booth #4410) iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced the first Xoft® Axxent® Electronic Brachytherapy (eBx®) System® in Spain is now available at the Hospital Miguel Servet for the treatment of early-stage breast cancer, non-melanoma skin cancer and gynecological cancers.
iCAD is highlighting the Xoft System at the third European Society for Radiotherapy and Oncology (ESTRO) Forum in Barcelona from April 24-28, 2015, where it will be available for demonstration at the Company's booth #4410.
"We are pleased with the increased adoption of the Xoft System in Europe for a variety of cancers due to its versatility and the important advantages it delivers to patients and healthcare providers," said Ken Ferry, CEO of iCAD. "The Xoft System is cleared to treat cancer anywhere in the body, requires minimal shielding and is mobile, allowing it to be used in different areas and facilities, including many smaller treatment rooms that may not accommodate larger equipment or protective shielding."
Also during the ESTRO forum, Dr. Paulo Costa, M.D., radiation oncologist of Instituto CUF Porto, Breast Surgery Unit, Senhora da Hora, Matosinhos, Portugal, will present an update on his clinical research, which examines patients who underwent intraoperative radiation therapy (IORT) treatment using the Xoft System during breast conserving surgery between April 2012 and November 2014.
"With a median 18 month follow-up clinical results continue to suggest that the Xoft System is safe with minimal side effects and low morbidity," said Dr. Costa. "As we continue to gather data, and patients and caregivers learn more about the benefits of IORT for the treatment of early-stage breast cancer, we are seeing increased patient demand for this radiation therapy option as a result of its much shorter course of treatment."
About Hospital Miguel Servet
The Hospital was founded in 1955 with the name "Residencia Jose Antonio". In 1971 it was extended with the Rehabilitation, Traumatology and Burns Hospital and the Maternity Hospital. In 1976 it undertook a multi-phase modernization program, converting over the years to form what since 1984 has been known as the "Hospital Miguel Servet". In 1999 the Hospital reached the category of University Hospital, under the name of the "Hospital Universitario Miguel Servet". In addition to undergraduate teaching the hospital offers training for residents in around forty specializations. The Hospital today is the largest in Aragon and among the first in Spain in terms of both volume as well as complexity. It has 1288 installed beds, 33 operating rooms and a long list of Units, with a reference population of over 800,000 inhabitants in the Autonomous Community of Aragon. Every year the hospital receives 46,000 admissions, offers 800,000 consultations and performs 37,000 surgeries. The hospital has an average occupation of over 76%, and 5500 employees. The hospital also has two national reference units (Burns and Multiple Sclerosis) as well as special reference units for all of Aragon and neighboring provinces.
About Xoft Axxent Electronic Brachytherapy System
The Xoft System is an isotope-free radiation treatment cleared by the U.S. Food and Drug Administration and CE marked in the EU for use anywhere in the body, including for the treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. The Xoft System requires only minimal shielding and therefore does not require room redesign or construction investment. Minimal shielding also allows medical personnel to remain in the room with the patient during treatment. The mobility of the Xoft System makes it easy to treat patients at multiple locations and to easily store the system when not in use. Xoft is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit www.xoftinc.com, like us on Facebook or follow us on Twitter at @xofticad.
About iCAD, Inc.
iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while enhancing patient care. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD's Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit www.icadmed.com or www.xoftinc.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company's ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "will", "continue", "anticipate", "likely", "seek", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC's website at http://www.sec.gov.
Contact:
For iCAD investor relations:
The Ruth Group
Zack Kubow / Courtney Dugan, +1-646-536-7030 /7024
www.theruthgroup.com
iCAD@theruthgroup.com
or
For iCAD media inquiries:
Berry & Company Public Relations, LLC
Lynn Granito, +1-212-253-8881
lgranito@berrypr.com
Share this article